This post was originally published on this site Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative, advanced or metastatic breast cancer who had been treated previously with endocrine therapy, a Phase 3 clinical trial shows. The findings were presented in a late-breaking presentation, “MONARCH 2: Overall survival of…
This post was originally published on this site Delivering higher doses of radiation therapy over a shorter time period — an approach called stereotactic body radiation therapy (SBRT) — does not worsen side effects in men with localized prostate cancer, compared to conventional radiation therapy, a Phase 3 trial shows. The study also suggests that…
This post was originally published on this site Treatment with Adcetris (brentuximab vedotin) is most effective in people with relapsed or refractory Hodgkin’s lymphoma who have chemotherapy-sensitive disease, and when used as consolidation therapy immediately after stem cell transplant, a study found. The findings were presented at the 2019 European Society for Medical Oncology (ESMO)…
This post was originally published on this site Add-on treatment with Erleada (apalutamide) lowers the risk of death by 25% in men on androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastases, according to updated results of a Phase 3 trial. The research, “Apalutamide (APA) and Overall…
This post was originally published on this site Leap Therapeutics’s investigational therapy DKN-01, alone or in combination with Taxol (paclitaxel), leads to significantly better responses in women with relapsed endometrial or ovarian cancer whose tumors have high levels of the Dickkopf-1 (DKK1) protein, or specific mutations in the Wnt signaling pathway, according to results of a Phase 2…
This post was originally published on this site A combination of Darzalex (daratumumab), Kyprolis (carfilzomib), and dexamethasone increases the time to disease progression or death in multiple myeloma patients who already have received one to three prior therapies. With those results, the CANDOR Phase 3 trial (NCT03158688), co-sponsored by Amgen and Janssen, achieved its primary goal…
This post was originally published on this site Tecentriq (atezolizumab) prolongs the lives of patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC) when administered as a first-line therapy, compared to chemotherapy, according to the interim analysis of a Phase 3 clinical trial. That finding was presented in a late-breaking presentation titled, “IMpower110:…
This post was originally published on this site Marking 20 years of support for breast cancer awareness and research, Hard Rock International has kicked off a host of efforts for its annual “PINKTOBER” campaign. Presented every October in observance of Breast Cancer Awareness Month, Hard Rock’s cafes, hotels, casinos and Rock Shops will raise money for the…
This post was originally published on this site The current scoring system used to assess the urgency of lung transplants, called LAS (lung allocation score), fails to predict the risk of death in people with sarcoidosis, a single center study suggests. The study “Mortality for sarcoidosis patients on the transplant wait list in the Lung…
This post was originally published on this site Treating non-Hodgkin’s lymphoma patients with radiation before giving them CAR T-cell therapy may lessen the likelihood of them experiencing toxic side effects, a small study suggests. This finding was detailed at the 2019 American Society for Radiation Oncology Annual Meeting, in the presentation “Induction Radiation Prior to Commercial Chimeric…
